北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study
作者: Zhang, X. W.1; Li, Chun1; Ma, X. X.1; Zhao, J. X.2; An, Yuan1; Liu, Shuang1; Li, Yan1; Li, Z. G.1
关键词: Cyclophosphamide ; Lupus nephritis ; Menstrual disturbance
刊名: CLINICAL RHEUMATOLOGY
发表日期: 2014-07-01
DOI: 10.1007/s10067-014-2590-6
卷: 33, 期:7, 页:939-945
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Rheumatology
研究领域[WOS]: Rheumatology
关键词[WOS]: RANDOMIZED CONTROLLED-TRIAL ; OVARIAN FAILURE ; IMMUNOSUPPRESSIVE THERAPY ; PULSE CYCLOPHOSPHAMIDE ; MYCOPHENOLATE-MOFETIL ; ERYTHEMATOSUS ; AZATHIOPRINE ; PREDNISOLONE ; GLOMERULONEPHRITIS ; METHYLPREDNISOLONE
英文摘要:

Cyclophosphamide (CYC) has long been considered a gold standard in inducing renal remission and preventing renal flares for patients with systemic lupus erythematosus (SLE). However, the rational use of CYC has not reached a consensus, such as the timing and length of treatment, the route of administration, and the ideal dosage. The objective of this study was to assess the efficacy and safety of short-interval lower-dose (SILD) intravenous (IV) CYC in the treatment of SLE. A total of 225 patients with lupus nephritis were randomly assigned to a 1-year trial, either the SILD group (12 fortnightly pulses at a fixed dose of 400 mg followed by 6 monthly pulses) or high-dose (HD) group (6 monthly pulses followed by two quarterly pulses at a dose of 0.5 similar to 1.0 g/m(2)). At 6 months of treatment, 28 % (30/107) of patients in the SILD group reached a complete remission (CR), and 51.4 % (55/107) were in partial remission (PR), as compared with 32.7 % (35/107) and 45.8 % (49/107) in the HD group, respectively. Serum albumin, 24-h urinary protein, and the scores of disease activity were significantly improved in both groups at 6 months and maintained at the end of clinical trial. However, the SILD group showed much less menstrual disturbances (11.5 %), gastrointestinal adverse effects (5.3 %), and leukopenia (9.7 %) than the HD group (28.6, 26.8, and 19.8 %, respectively) at the end of clinical trial. The efficacy of the short-interval lower-dose (SILD) IV CYC regimen in the treatment of lupus nephritis is equivalent to that of the high-dose (HD) regimen, whereas the incidence of adverse events is much lower in the SILD group.

语种: 英语
WOS记录号: WOS:000338324000009
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65052
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Dept Rheumatol & Immunol, Beijing 100044, Peoples R China
2.Peking Univ, Hosp 3, Dept Rheumatol & Immunol, Beijing 100191, Peoples R China

Recommended Citation:
Zhang, X. W.,Li, Chun,Ma, X. X.,et al. Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study[J]. CLINICAL RHEUMATOLOGY,2014,33(7):939-945.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhang, X. W.]'s Articles
[Li, Chun]'s Articles
[Ma, X. X.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhang, X. W.]‘s Articles
[Li, Chun]‘s Articles
[Ma, X. X.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace